Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Biden and Pelosi pursuing plans to cap drug prices

By Brian Buntz | July 9, 2021

Joe Biden and Nancy Pelosi

Joe Biden and Nancy Pelosi images from Wikipedia

President Biden has instructed FDA to develop a plan to import prescription drugs from Canada while asking federal officials to create a “comprehensive plan” to cut drug prices within 45 days.

Biden has also recommended that FTC block “pay for delay” agreements from pharma companies paying generic drug makers to hold off on introducing competitive products.

The proposals are included in a far-reaching executive order with several healthcare provisions. The main thrust of the order, however, is stimulating competition in the economy.

Earlier this year, Biden asked Congress to allow Medicare to negotiate drug prices, which was also a goal spelled out in the 2019 House Bill H.R. 3 that Democrats reintroduced in April.

Biden included the recent effort to give Medicare drug negotiation powers in an executive order intended to spur economic competition.

While the Trump administration also intended to open up prescription drug imports, the proposal ultimately stalled.

Speaker Nancy Pelosi (D-Calif.) recently announced that she was pursuing drug pricing reform in conjunction with President Biden’s $4 trillion infrastructure initiative unveiled in spring.

Pelosi argued that drug pricing reform would not hurt R&D spending, which is a central argument drug companies have used to criticize efforts to cap expenditures on medicines. She pointed to a recent staff report from the House Committee on Oversight and Reform to support that argument. The report found that 14 of the largest drug companies spent more on stock buybacks, dividends and executive compensation than R&D. It also concluded that many drug companies spend a significant amount of R&D funds on strategies to suppress competition instead of developing new drugs.

In addition to allowing Medicare to negotiate drug prices, Pelosi is also seeking to cap the prices pharmaceutical companies charge private payers.

Pelosi has recommended that Congressional Democrats use budget reconciliation to enact the drug pricing reform provisions. The process requires a simple majority and is immune from the filibuster.

Comments

  1. sam says

    July 13, 2021 at 5:03 pm

    It sounds good to those who have tunnel vision. The high drug prices are a result of the Real Problem. Big-Pharma coupled with the FDA are serving the Money. They have Little to No Invested Interest in the Health of the People. All their Investments are in the Money, Stocks etc. We have conflicts of interest within the FDA. It seems as members of the FDA have Stock Investments in Drug Companies. Iv’e even heard stories of members actually Owning Drug Companies. Major Conflicts!

    Reply

Tell Us What You Think! Cancel reply

Related Articles Read More >

Biogen logo
Biogen is scaling back space outside Boston
Fresenius Kabi
Fresenius Kabi plans to add 2D barcodes to its pharmaceutical portfolio
Dollars for drugs
Democrats’ drug pricing plan attracts pushback from Republicans
GBT/Pfizer
Pfizer to scoop up Global Blood Therapeutics for $5.4 billion 

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards